STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRBD
  4. [Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity

Spruce Biosciences (SPRB) chair receives grant of 1,700 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.

Positive

  • None.

Negative

  • None.
Insider GREY MICHAEL G
Role Executive Chairman
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 1,700 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 1,700 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 1,700 options Stock Option (Right to Buy) covering common stock
Exercise price $52.70 per share Conversion or exercise price of granted options
Underlying shares 1,700 shares Common Stock underlying the options
Post-grant derivative holdings 1,700 options Total derivative securities following transaction
Expiration date May 20, 2036 Option expiration if not exercised earlier
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
2020 Equity Incentive Plan financial
"Continuous Service (as defined in the 2020 Equity Incentive Plan"
Continuous Service financial
"subject to the Reporting Person's Continuous Service (as defined"
Change in Control financial
"will vest in full upon a Change in Control (as defined"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GREY MICHAEL G
(Last)(First)(Middle)
C/O SPRUCE BIOSCIENCES, INC.
611 GATEWAY BOULEVARD, SUITE 740
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Executive Chairman
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$52.705/21/2026A1,700 (1)05/20/2036Common Stock1,700$01,700D
Explanation of Responses:
1. The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
/s/ Samir Gharib, Attorney-in-Fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did SPRB Executive Chairman Michael Grey report?

Michael Grey reported receiving a grant of 1,700 stock options for Spruce Biosciences common shares. The options were granted at an exercise price of $52.70 per share and are part of his equity-based compensation as Executive Chairman.

What is the exercise price and size of Michael Grey’s SPRB option grant?

The grant covers 1,700 stock options with an exercise price of $52.70 per share. This means Grey can buy up to 1,700 Spruce Biosciences common shares at $52.70 once the options vest.

When do Michael Grey’s newly granted SPRB stock options vest?

The options vest on the first anniversary of the grant date and will in any case be fully vested by Spruce Biosciences’ 2027 annual stockholder meeting. Vesting is conditioned on Grey’s continuous service under the 2020 Equity Incentive Plan.

How does a Change in Control affect Michael Grey’s SPRB stock options?

In the event of a Change in Control, Grey’s 1,700 stock options will vest in full. This acceleration provision, defined in the 2020 Equity Incentive Plan, allows all granted options to become exercisable if control of Spruce Biosciences changes.

How many SPRB derivative securities does Michael Grey hold after this grant?

Following this transaction, Grey holds 1,700 derivative securities in the form of stock options. These options each relate to one share of Spruce Biosciences common stock and expire on May 20, 2036 if not exercised earlier.